These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 27102725)

  • 1. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
    Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H
    Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
    Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
    Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
    J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
    Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
    J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
    Kazankov K; Barrera F; Møller HJ; Bibby BM; Vilstrup H; George J; Grønbaek H
    Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease.
    Kazankov K; Alisi A; Møller HJ; De Vito R; Rittig S; Mahler B; Nobili V; Grønbæk H
    J Pediatr Gastroenterol Nutr; 2018 Nov; 67(5):635-642. PubMed ID: 30074574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
    Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
    J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.
    Dultz G; Gerber L; Farnik H; Berger A; Vermehren J; Pleli T; Zeuzem S; Piiper A; Kronenberger B; Waidmann O
    J Viral Hepat; 2015 Apr; 22(4):427-32. PubMed ID: 25181653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease.
    Rødgaard-Hansen S; St George A; Kazankov K; Bauman A; George J; Grønbæk H; Jon Møller H
    Scand J Clin Lab Invest; 2017 Nov; 77(7):498-504. PubMed ID: 28715286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children.
    Kazankov K; Møller HJ; Lange A; Birkebaek NH; Holland-Fischer P; Solvig J; Hørlyck A; Kristensen K; Rittig S; Handberg A; Vilstrup H; Grønbaek H
    Pediatr Obes; 2015 Jun; 10(3):226-33. PubMed ID: 25073966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.
    Kazankov K; Rode A; Simonsen K; Villadsen GE; Nicoll A; Møller HJ; Lim L; Angus P; Kronborg I; Arachchi N; Gorelik A; Liew D; Vilstrup H; Frystyk J; Grønbæk H
    Scand J Clin Lab Invest; 2016; 76(1):64-73. PubMed ID: 26549495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection.
    Tornai T; Vitalis Z; Sipeki N; Dinya T; Tornai D; Antal-Szalmas P; Karanyi Z; Tornai I; Papp M
    Liver Int; 2016 Nov; 36(11):1628-1638. PubMed ID: 27031405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
    Lund Laursen T; Brøckner Siggard C; Kazankov K; Damgaard Sandahl T; Møller HJ; Ong A; Douglas MW; George J; Tarp B; Hagelskjaer Kristensen L; Lund Laursen A; Hiramatsu A; Nakahara T; Chayama K; Grønbaek H
    Scand J Gastroenterol; 2018 Aug; 53(8):986-993. PubMed ID: 29987961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of serum CD163 as a marker of fibrosis in patients with NAFLD.
    Ragab HM; El Maksoud NA; Amin MA; Elaziz WA
    Diabetes Metab Syndr; 2021; 15(1):87-92. PubMed ID: 33310266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of circulating markers of hepatic apoptosis and inflammation in obese children with and without obstructive sleep apnea.
    Alkhouri N; Kheirandish-Gozal L; Matloob A; Alonso-Álvarez ML; Khalyfa A; Terán-Santos J; Okwu V; Lopez R; Gileles-Hillel A; Dweik R; Gozal D
    Sleep Med; 2015 Sep; 16(9):1031-5. PubMed ID: 26298775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study.
    Andersen ES; Rødgaard-Hansen S; Moessner B; Christensen PB; Møller HJ; Weis N
    Eur J Clin Microbiol Infect Dis; 2014 Jan; 33(1):117-22. PubMed ID: 24424890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage markers soluble CD163 and soluble mannose receptor are associated with liver injury in patients with paracetamol overdose.
    Siggaard CB; Kazankov K; Rødgaard-Hansen S; Møller HJ; Donnelly MC; Simpson KJ; Grønbaek H
    Scand J Gastroenterol; 2019 May; 54(5):623-632. PubMed ID: 31067143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
    Grønbaek H; Sandahl TD; Mortensen C; Vilstrup H; Møller HJ; Møller S
    Aliment Pharmacol Ther; 2012 Jul; 36(2):173-80. PubMed ID: 22591184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-centre experience of the macrophage activation marker soluble (s)CD163 - associations with disease activity and treatment response in patients with autoimmune hepatitis.
    Grønbaek H; Kreutzfeldt M; Kazankov K; Jessen N; Sandahl T; Hamilton-Dutoit S; Vilstrup H; J Møller H
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1062-1070. PubMed ID: 27679428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.